Patent Issued for Prostate cancer chimeric antigen receptors (USPTO 12037605).

Kite Pharma Inc. has been issued a patent for prostate cancer chimeric antigen receptors. The patent describes an antibody or antigen binding fragment that targets prostate-specific membrane antigen (PSMA), a protein found in prostate cancer cells. The antibody contains specific sequences of heavy chain complementarity determining regions (HCDRs) and light chain complementarity determining regions (LCDRs). This invention aims to improve the ability of T cells to target and eliminate prostate cancer cells. The patent also includes claims for a chimeric antigen receptor, a nucleic acid encoding the receptor, a recombinant vector containing the nucleic acid, a method of treating prostate cancer using the antibody, and a method of stimulating an immune response against prostate cancer. The patent was filed by Matthew Drever and published in 2024. [Extracted from the article]

Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)